Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/13/22 | 10-Q/A | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
47 |
| 10/11/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
87 |
| 10/04/22 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/04/22 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/04/22 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 09/30/22 | EFFECT | Notice of Effectiveness |
|
1 | |
| 09/28/22 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 09/28/22 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
30 | |
| 09/26/22 | RW | Registration Withdrawal Request |
|
2 | |
| 09/22/22 | 4 | Statement of changes in beneficial ownership of securities |
|
1 |
